NW Bio Announces financings Totalling $35 Million to Expand and Accelerate DCVax-L and DCVax-Direct Programs

Funding Includes $25 Million Equity Investment By Leading UK Investment Fundand $10 Million Mortgage Financing BETHESDA, Md., Nov. 19, 2014 /PRNewswire/ — Northwest Biotherapeutics (NASDAQ: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today two financings totaling $35 million.  The financings include a $25 million equity investment by UK based C.F. Woodford Equity …

NW BIO Announces Completion of DCVAX®-DIRECT Phase I Trial Recruitment

DCVax®-Direct Phase II Trial Preparations and Manufacturing Expansion Underway July 16, 2014 Northwest Biotherapeutics (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the Phase I portion of the Company’s Phase I/II DCVax-Direct clinical trial has completed its 36-patient target recruitment, and the Company is now underway with preparations for the Phase …

The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Violations of Federal Securities Laws by the Board of Directors of Northwest Biotherapeutics, Inc.

June 25, 2014 Levi & Korsinsky, LLP is investigating Northwest Biotherapeutics, Inc. (“Northwest Bio” or the “Company”) in connection with possible breaches of federal securities laws. The investigation regards concerns that the Company made misleading statements regarding its clinical trial for DC-Vax Direct, its experimental cancer vaccine. To get more information, click here: http://zlk.9nl.com/northwest-biotherapeutics-nwbo. There is no cost or obligation to …

NW Bio Announces First Data From Ongoing DCVax-Direct Trial

First Case Study Announced While Broader Data Being Collected; Evidence Indicates Substantial Tumor Necrosis and Initial Tumor Regression May 15, 2014 Northwest Biotherapeutics, a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today provided an initial patient case study, showing signs of tumor necrosis (tumor death) and initial tumor regression, from the Company’s ongoing DCVax-Direct trial for …

NW Bio Announces German Early Access and Reimbursement Approvals for DCVax-L

DCVax-L Is First Product of Its Kind to Receive Hospital Exemption from German Regulator March 10, 2014  Northwest Biotherapeutics, a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it has received approval from the Paul Ehrlich Institute (“PEI”- the FDA of Germany) of a “Hospital Exemption” early access program under Section 4b of the …